# Varegacestat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/varegacestat

> The PDUFA target action date for varegacestat, sponsored by Immunome Inc. (IMNM), is April 28, 2027, for desmoid tumors. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the varegacestat PDUFA date?

The PDUFA target action date for varegacestat, sponsored by Immunome Inc. (IMNM), is April 28, 2027, for desmoid tumors. Status: scheduled. Press release filed with the SEC (EX-99): "Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)" Last confirmed November 9, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/varegacestat)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-453556, https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/varegacestat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | varegacestat |
| Codes | AL102 |
| Sponsor | Immunome Inc. (IMNM) https://sec-api.dev/companies/imnm/catalysts |
| Indications | progressing desmoid tumors, [desmoid tumors](https://sec-api.dev/indications/desmoid-tumors), with desmoid tumors, desmoid tumors planned for 2q 2026, Desmoid |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### March 31, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-05-12, last confirmed 2025-05-12.
- SEC Form 10-Q (accession 0001558370-25-007382): "(2) The increase for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to increased clinical trial activities as we initiated our Phase 1 trial in February 2025." https://www.sec.gov/Archives/edgar/data/1472012/000155837025007382/tmb-20250331x10q.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Indication: desmoid tumors.
- First seen 2024-11-13, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-025558): "We particularly look forward to topline data in the second half of 2025 for the RINGSIDE trial of varegacestat, which we believe will demonstrate significant benefits for patients with desmoid tumors."" https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-117682): ""Topline data for the RINGSIDE Part B trial of AL102 is expected in the second half of 2025, and IND submissions for IM-1021 and IM-3050 are on track."" https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/tm2428220d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-269538): ""We anticipate the release of topline data for the RINGSIDE trial of varegacestat before the end of this year, to be followed by an NDA submission if warranted."" https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-104015): ""We look forward to sharing topline data for the RINGSIDE trial of varegacestat before the end of this year, and we are well-positioned to support a new drug application submission for that program as appropriate."" https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/imnm-ex99_1.htm

### December 3, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Desmoid; Desmoid Tumor.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04871282 (A Study of AL102 in Patients With Progressing Desmoid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-12-03 (ACTUAL); Lead Sponsor Immunome, Inc.." https://clinicaltrials.gov/study/NCT04871282

### December 15, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: desmoid tumors.
- First seen 2024-11-13, last confirmed 2026-11-09.
- SEC Form 8-K (accession 0001193125-25-318429): "On December 15, 2025, Immunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088141): "In December 2025, Immunome announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-453597): "In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344636): "In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219425): "In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312526219425/imnm-20260331.htm
- SEC Form 10-K (accession 0001193125-26-088172): "In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm
- SEC Form 10-Q (accession 0001193125-26-453597): "In December 2025, we reported positive Phase 3 RINGSIDE (Part B) topline results and, in May 2026, detailed efficacy and safety results were presented at the 2026 American Society of Clinical Oncology Annual Meeting." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344636): "In December 2025, we reported positive Phase 3 RINGSIDE (Part B) topline results and, in May 2026, detailed efficacy and safety results were presented at the 2026 American Society of Clinical Oncology Annual Meeting." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219425): "In December 2025, we reported positive Phase 3 RINGSIDE (Part B) topline results showing that the study met all primary and key secondary endpoints." https://www.sec.gov/Archives/edgar/data/1472012/000119312526219425/imnm-20260331.htm
- SEC Form 10-K (accession 0001193125-26-088172): "In December 2025, we reported positive Phase 3 RINGSIDE (Part B) topline results showing that the study met all primary and key secondary endpoints." https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-269538): "Varegacestat: Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025." https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-047304): "Varegacestat: Full enrollment for the Phase 3 RINGSIDE Part B study of varegacestat for the treatment of desmoid tumors was completed in February 2024, and Immunome expects to report topline data for RINGSIDE Part B in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_ex99-1.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: desmoid tumors planned for 2Q 2026.
- First seen 2025-12-15, last confirmed 2026-03-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088141): "New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026" https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088141): "The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in the second quarter of 2026," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome." https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088141): "Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration for varegacestat in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-318429): "New Drug Application submission to U.S. FDA planned for Q2 2026" https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961dex991.htm
- SEC Form 8-K (accession 0001193125-25-318429): "Based on these data, the Company plans to submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026." https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm

### Apr 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-09, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001193125-26-453597): "We are monitoring these regulations as several of our programs move into later stages of development, including varegacestat for which we submitted an NDA in April 2026, which was accepted by the FDA and assigned a PDUFA date of April 28, 2027; however, a majority of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm

### Apr 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: with desmoid tumors.
- First seen 2026-05-12, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219367): "In April 2026, Immunome submitted an NDA to the U.S. FDA for varegacestat for the treatment of adults with desmoid tumors." https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-219425): "We submitted a new drug application, or NDA, for varegacestat in April 2026, and we plan to submit a marketing authorization application, or MAA, with the European Medicines Agency, or EMA, by the end of 2026." https://www.sec.gov/Archives/edgar/data/1472012/000119312526219425/imnm-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-219425): "We submitted an NDA for varegacestat in April 2026, and we plan to submit an MAA with the EMA by the end of 2026." https://www.sec.gov/Archives/edgar/data/1472012/000119312526219425/imnm-20260331.htm

### Jul 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-08-11, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453556): "The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344577): "In July 2026, the U.S. FDA accepted Immunome's NDA for varegacestat for the treatment of adults with desmoid tumors and assigned a PDUFA target action date of April 28, 2027." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm

### April 28, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3. Indication: desmoid tumors.
- First seen 2026-08-11, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453556): "Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)" https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453556): ""We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453556): "The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344577): "Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors" https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344577): ""For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344577): "In July 2026, the U.S. FDA accepted Immunome's NDA for varegacestat for the treatment of adults with desmoid tumors and assigned a PDUFA target action date of April 28, 2027." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-453597): "We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-453597): "We also have limited experience as a company in preparing and submitting marketing applications and, although we recently submitted an MAA for varegacestat to the EMA and an NDA for varegacestat to the FDA, which was assigned a PDUFA target action date of April 28, 2027, we have not previously submitted a BLA." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-453597): "We are monitoring these regulations as several of our programs move into later stages of development, including varegacestat for which we submitted an NDA in April 2026, which was accepted by the FDA and assigned a PDUFA date of April 28, 2027; however, a majority of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years." https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344636): "We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-344636): "We also have limited experience as a company in preparing and submitting marketing applications and, although we recently submitted an NDA for varegacestat, which has been accepted by the FDA and assigned a PDUFA target action date of April 28, 2027, we have not previously submitted a BLA, or foreign regulatory submission comparable to an NDA or BLA for any product candidate." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-344636): "We are monitoring these regulations as several of our programs move into later stages of development, including varegacestat for which we submitted an NDA in the second quarter 2026, which was accepted by the FDA and assigned a PDUFA date of April 28, 2027; however, a majority of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years." https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm

## Same indication

- [Zolucatetide](https://sec-api.dev/pdufa/zolucatetide) (PBLS)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/varegacestat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Varegacestat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/varegacestat

```bibtex
@misc{secapidev_pdufa_varegacestat_20261116,
  title        = {Varegacestat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/varegacestat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_varegacestat_20261116","title":"Varegacestat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/varegacestat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
